Skip to main content

Table 1 Patient characteristics

From: Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer

   nab-PTX plus RAM PTX plus RAM P value
N = 113 % N = 138 %
Age Median (range) 67 (25–84)   69 (40–85)   0.16
> 65 71 62.8 96 69.6 0.261
Sex Male 78 69 88 63.8 0.381
Female 35 31 50 36.2 0.381
ECOG PS 0 85 75.2 88 63.8 0.051
1 25 22.1 43 31.2 0.109
> 2 3 2.7 7 5.1 0.261
Previous gastrectomy Yes 35 31 41 29.7 0.828
No 78 69 97 70.3 0.828
Recurrence during adjuvant chemotherapy 6 5.3 8 5.8 0.867
Time to progressive disease on first-line therapy < 6 months 75 66.4 78 56.5 0.112
> 6 months 38 33.6 60 43.5 0.112
HER2 Positive 13 11.5 23 16.7 0.246
Negative 99 87.6 112 81.1 0.165
Unknown 1 0.9 3 2.2 0.39
Histology Diffuse 69 61.1 82 59.4 0.792
Intestinal 43 38.1 52 37.7 0.952
Mix, Missing 1 0.9 4 2.9 0.254
Number of metastatic sites 0–1 60 54 62 44.9 0.198
2 33 28.3 48 36.2 0.347
> 3 20 17.7 28 18.9 0.604
Metastatic site Liver 32 28.3 46 33.3 0.393
Lung 18 15.9 19 13.8 0.631
Lymph node 54 47.8 74 53.6 0.358
Peritoneum 70 61.9 80 58 0.523
Others 13 11.5 26 18.8 0.11
Prior therapy Fluoropyrimidine 113 100 138 100
Platinum 107 94.7 130 94.2 0.867
Trastuzumab 10 8.8 21 15.2 0.127
Ascites None 59 52.2 75 54.3 0.736
Small 22 19.5 20 14.5 0.293
Moderate 14 12.4 15 10.9 0.708
Massive 18 15.9 28 20.3 0.374
None/small 81 71.7 95 68.8 0.625
Moderate/massive 32 28.3 43 31.2 0.625
  1. nab-PTX nanoparticle albumin-bound paclitaxel, RAM ramucirumab, HER2 human epidermal growth factor receptor 2, ECOG PS Eastern Cooperative Oncology Group performance status
\